{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:26:05Z","timestamp":1772166365351,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric Mastocytosis is a rare and heterogeneous disease, characterized by accumulation of mast cells in the skin (Cutaneous Mastocytosis) and\/or, less frequently, in other organs, mainly liver, spleen, bone marrow, lymph nodes and gastrointestinal tract (Systemic Mastocytosis). Patients affected by Systemic Mastocytosis show symptoms caused by \u00a0a massive release of mast cell mediators: itching, flushing, abdominal pain, generalized weakness, fatigue and neuropsychiatric disorders. Moreover, children with Systemic Mastocytosis are at greater risk of anaphylactic\/anaphylactoid reactions, often poorly controlled by the conventional therapy with antihistamines, mast cells stabilizers and steroids. As a result, children affected by Systemic Mastocytosis have a poor quality of life and suffer the consequence of prolonged steroidal treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A child with Systemic Mastocytosis and severe symptoms, refractory to symptomatic and steroidal therapy, has been successfully treated with Omalizumab, an anti-IgE monoclonal antibody usually employed in allergic patients with severe asthma and orticaria. The onset of clinical benefit of Omalizumab therapy was extraordinarily rapid, but proved to be strictly dependent on drug administration. The child has become completely and steadily asymptomatic. No other anaphylactic episodes have been reported. Steroid treatment could be definitively withdrawn after the second dose of Omalizumab, and all the other medications were later reduced. Twenty months after beginning, Omalizumab therapy is still ongoing with good symptomatology control; no side effects have been observed so far.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our experience, Omalizumab is an effective treatment for children affected by Systemic Mastocytosis not responding to conventional medical treatments. The main strengths of this therapy are its rapid and extraordinary efficacy to control the severe mast cells mediator-related symptoms, the lack of side effects and its steroid-sparing effect. However, more extensive and controlled studies in pediatric patients affected by Systemic Mastocytosis are needed to substantiate these promising findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13052-022-01402-7","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T19:03:38Z","timestamp":1673636618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications"],"prefix":"10.1186","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-9757","authenticated-orcid":false,"given":"Grazia","family":"Bossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Brazzelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"De Amici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Pietra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Raviola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Naso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Regalbuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Boselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Fortina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Luigi","family":"Marseglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"issue":"2","key":"1402_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1056\/NEJMra1409760","volume":"373","author":"TC Theoharides","year":"2015","unstructured":"Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373(2):163\u201372. https:\/\/doi.org\/10.1056\/NEJMra1409760.","journal-title":"N Engl J Med"},{"issue":"11","key":"1402_CR2","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere. 2021;5(11):e646. https:\/\/doi.org\/10.1097\/HS9.0000000000000646.","journal-title":"Hemasphere"},{"issue":"11","key":"1402_CR3","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","volume":"129","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420\u20137. https:\/\/doi.org\/10.1182\/blood-2016-09-731893.","journal-title":"Blood"},{"issue":"3","key":"1402_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.iac.2018.04.001","volume":"38","author":"A Matito","year":"2018","unstructured":"Matito A, Aza\u00f1a JM, Torrelo A, Alvarez-Twose I. Cutaneous mastocytosis in adults and children: new classification and prognostic factors. Immunol Allergy Clin N Am. 2018;38(3):351\u201363. https:\/\/doi.org\/10.1016\/j.iac.2018.04.001.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"4","key":"1402_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/MOP.0000000000000922","volume":"32","author":"SH Hussain","year":"2020","unstructured":"Hussain SH. Pediatric mastocytosis. Curr Opin Pediatr. 2020;32(4):531\u20138. https:\/\/doi.org\/10.1097\/MOP.0000000000000922.","journal-title":"Curr Opin Pediatr"},{"issue":"5","key":"1402_CR6","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.3390\/ijms22052586","volume":"22","author":"M Lange","year":"2021","unstructured":"Lange M, Hartmann K, Carter MC, et al. Molecular background, clinical features and management of pediatric mastocytosis: status 2021. Int J Mol Sci. 2021;22(5):2586. https:\/\/doi.org\/10.3390\/ijms22052586.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1402_CR7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/modpathol.2015.72","volume":"28","author":"M Jara-Acevedo","year":"2015","unstructured":"Jara-Acevedo M, Teodosio C, Sanchez-Mu\u00f1oz L, et al. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol. 2015;28(8):1138\u201349. https:\/\/doi.org\/10.1038\/modpathol.2015.72.","journal-title":"Mod Pathol"},{"issue":"1","key":"1402_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.iac.2016.08.017","volume":"37","author":"A Schuch","year":"2017","unstructured":"Schuch A, Brockow K. Mastocytosis and anaphylaxis. Immunol Allergy Clin N Am. 2017;37(1):153\u201364. https:\/\/doi.org\/10.1016\/j.iac.2016.08.017.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"5","key":"1402_CR9","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.3390\/ijms22052684","volume":"22","author":"K Brockow","year":"2021","unstructured":"Brockow K, Plata-Nazar K, Lange M, Nedoszytko B, Niedoszytko M, Valent P. Mediator-related symptoms and anaphylaxis in children with mastocytosis. Int J Mol Sci. 2021;22(5):2684. https:\/\/doi.org\/10.3390\/ijms22052684.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1402_CR10","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","volume":"7","author":"M Castells","year":"2019","unstructured":"Castells M, Butterfield J. Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management. J Allergy Clin Immunol Pract. 2019;7(4):1097\u2013106. https:\/\/doi.org\/10.1016\/j.jaip.2019.02.002.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"1402_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1573398X13666170616110738","volume":"13","author":"A Licari","year":"2017","unstructured":"Licari A, Castagnoli R, Panfili E, Marseglia A, Brambilla I, Marseglia GL. An update on anti-IgE therapy in pediatric respiratory diseases. Curr Respir Med Rev. 2017;13(1):22\u20139. https:\/\/doi.org\/10.2174\/1573398X13666170616110738.","journal-title":"Curr Respir Med Rev"},{"issue":"1","key":"1402_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/1573398X13666170426094536","volume":"13","author":"A Licari","year":"2017","unstructured":"Licari A, Castagnoli R, Denicol\u00f2 C, et al. Omalizumab in Childhood Asthma Italian Study Group. Omalizumab in children with severe allergic asthma: the Italian real-life experience. Curr Respir Med Rev. 2017;13(1):36\u201342. https:\/\/doi.org\/10.2174\/1573398X13666170426094536.","journal-title":"Curr Respir Med Rev"},{"issue":"5","key":"1402_CR13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.23736\/S0026-4946.20.05993-9","volume":"72","author":"R Castagnoli","year":"2020","unstructured":"Castagnoli R, De Filippo M, Votto M, et al. An update on biological therapies for pediatric allergic diseases. Minerva Pediatr. 2020;72(5):364\u201371. https:\/\/doi.org\/10.23736\/S0026-4946.20.05993-9.","journal-title":"Minerva Pediatr"},{"key":"1402_CR14","doi-asserted-by":"publisher","first-page":"027","DOI":"10.23937\/2572-3308.1510027","volume":"4","author":"A Zampetti","year":"2018","unstructured":"Zampetti A. Mastocytosis: a new therapeutic scenario with omalizumab. Int J Aller Mediaction. 2018;4:027. https:\/\/doi.org\/10.23937\/2572-3308.1510027.","journal-title":"Int J Aller Mediaction"},{"issue":"7","key":"1402_CR15","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.jaip.2019.04.030","volume":"7","author":"CR Weiler","year":"2019","unstructured":"Weiler CR. Omalizumab and mast cell disorders: are we there yet? J Allergy Clin Immunol Pract. 2019;7(7):2396\u20137. https:\/\/doi.org\/10.1016\/j.jaip.2019.04.030.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"1402_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cea.13592","volume":"50","author":"F Jendoubi","year":"2020","unstructured":"Jendoubi F, Gaudenzio N, Gallini A, Negretto M, Paul C, Bulai Livideanu C. Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. Clin Exp Allergy. 2020;50(6):654\u201361. https:\/\/doi.org\/10.1111\/cea.13592.","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"1402_CR17","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","volume":"119","author":"MC Carter","year":"2007","unstructured":"Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007;119(6):1550\u20131. https:\/\/doi.org\/10.1016\/j.jaci.2007.03.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1402_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaci.2007.05.011","volume":"120","author":"F Siebenhaar","year":"2007","unstructured":"Siebenhaar F, K\u00fchn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and M\u00e9ni\u00e8re disease with anti-IgE therapy. J Allergy Clin Immunol. 2007;120(1):213\u20135. https:\/\/doi.org\/10.1016\/j.jaci.2007.05.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1402_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.anai.2010.04.011","volume":"104","author":"K Kontou-Fili","year":"2010","unstructured":"Kontou-Fili K, Filis CI, Voulgari C, Panayiotidis PG. Omalizumab monotherapy for bee sting and unprovoked \u201canaphylaxis\u201d in a patient with systemic mastocytosis and undetectable specific IgE. Ann Allergy Asthma Immunol. 2010;104(6):537\u20139. https:\/\/doi.org\/10.1016\/j.anai.2010.04.011.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"1402_CR20","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259","volume":"65","author":"JA Douglass","year":"2010","unstructured":"Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O\u2019Hehir RE. Omalizumab is effective in treating systemic mastocytosis in a non-atopic patient. Allergy. 2010;65(7):926\u20137. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02259.","journal-title":"Allergy"},{"issue":"6","key":"1402_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2169\/internalmedicine.50.4640","volume":"50","author":"GJ Molderings","year":"2011","unstructured":"Molderings GJ, Raithel M, Kratz F, et al. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. Intern Med. 2011;50(6):611\u20135. https:\/\/doi.org\/10.2169\/internalmedicine.50.4640.","journal-title":"Intern Med"},{"issue":"2","key":"1402_CR22","first-page":"52","volume":"45","author":"G Paraskevopoulos","year":"2013","unstructured":"Paraskevopoulos G, Sifnaios E, Christodoulopoulos K, Mantopoulou F, Papakonstantis M, Sabaziotis D. Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy. Eur Ann Allergy Clin Immunol. 2013;45(2):52\u20135.","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"3","key":"1402_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","volume":"2","author":"KC Sokol","year":"2014","unstructured":"Sokol KC, Ghazi A, Kelly BC, Grant JA. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract. 2014;2(3):266\u201370. https:\/\/doi.org\/10.1016\/j.jaip.2014.03.009.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"1402_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2340\/00015555-1687","volume":"94","author":"L Kibsgaard","year":"2014","unstructured":"Kibsgaard L, Skjold T, Deleuran M, Vestergaard C. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis. Acta Derm Venereol. 2014;94(3):363\u20134. https:\/\/doi.org\/10.2340\/00015555-1687.","journal-title":"Acta Derm Venereol"},{"key":"1402_CR25","doi-asserted-by":"publisher","unstructured":"Lieberoth S, Thomsen SF. Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab. Case Rep Med. 2015:903541. https:\/\/doi.org\/10.1155\/2015\/903541.","DOI":"10.1155\/2015\/903541"},{"issue":"4","key":"1402_CR26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jaip.2018.07.041","volume":"7","author":"GM Constantine","year":"2019","unstructured":"Constantine GM, Bressler PB, Petroni D, Metcalfe DD, Carter MC. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis. J Allergy Clin Immunol Pract. 2019;7(4):1314\u20136. https:\/\/doi.org\/10.1016\/j.jaip.2018.07.041.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"1402_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/all.13237","volume":"73","author":"S Broesby-Olsen","year":"2018","unstructured":"Broesby-Olsen S, Vestergaard H, Mortz CG, et al. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations. Allergy. 2018;73(1):230\u20138. https:\/\/doi.org\/10.1111\/all.13237.","journal-title":"Allergy"},{"key":"1402_CR28","doi-asserted-by":"publisher","first-page":"3787586","DOI":"10.1155\/2019\/3787586","volume":"2019","author":"C Slapnicar","year":"2019","unstructured":"Slapnicar C, Trinkaus M, Hicks L, Vadas P. Efficacy of Omalizumab in indolent systemic mastocytosis. Case Rep Hematol. 2019;2019:3787586. https:\/\/doi.org\/10.1155\/2019\/3787586.","journal-title":"Case Rep Hematol"},{"issue":"7","key":"1402_CR29","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","volume":"7","author":"R Lemal","year":"2019","unstructured":"Lemal R, Fouquet G, Terriou L, et al. Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS. J Allergy Clin Immunol Pract. 2019;7(7):2387\u20132395.e3. https:\/\/doi.org\/10.1016\/j.jaip.2019.03.039.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"1402_CR30","doi-asserted-by":"publisher","first-page":"e12848","DOI":"10.1111\/dth.12848","volume":"32","author":"T Hinojosa","year":"2019","unstructured":"Hinojosa T, Lewis DJ, Vangipuram R, et al. The efficacy of omalizumab in cutaneous mastocytosis: a case series. Dermatol Ther. 2019;32(3):e12848. https:\/\/doi.org\/10.1111\/dth.12848.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1402_CR31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000504842","volume":"236","author":"M Distler","year":"2020","unstructured":"Distler M, Maul JT, Steiner UC, et al. Efficacy of Omalizumab in mastocytosis: allusive indication obtained from a prospective, double-blind, multicenter study (XOLMA study). Dermatology. 2020;236(6):529\u201339. https:\/\/doi.org\/10.1159\/000504842.","journal-title":"Dermatology"},{"issue":"2","key":"1402_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jaci.2010.05.043","volume":"126","author":"TJ Pitt","year":"2010","unstructured":"Pitt TJ, Cisneros N, Kalicinsky C, Becker AB. Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol. 2010;126(2):415\u20136. https:\/\/doi.org\/10.1016\/j.jaci.2010.05.043.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1402_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.anai.2012.02.021","volume":"108","author":"MC Bell","year":"2012","unstructured":"Bell MC, Jackson DJ. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol. 2012;108(5):383\u20134. https:\/\/doi.org\/10.1016\/j.anai.2012.02.021.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"1402_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.anai.2013.08.014","volume":"111","author":"A Matito","year":"2013","unstructured":"Matito A, Bl\u00e1zquez-Go\u00f1i C, Morgado JM, et al. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol. 2013;111(5):425\u20136. https:\/\/doi.org\/10.1016\/j.anai.2013.08.014.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"1402_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/ced.13408","volume":"43","author":"JDM Hughes","year":"2018","unstructured":"Hughes JDM, Olynyc T, Chapdelaine H, Segal L, Miedzybrodzki B, Ben-Shoshan M. Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair\u00ae ). Clin Exp Dermatol. 2018;43(5):573\u20136. https:\/\/doi.org\/10.1111\/ced.13408.","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"1402_CR36","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/all.12920","volume":"71","author":"B Van Anrooij","year":"2016","unstructured":"Van Anrooij B, Kluin-Nelemans JC, Safy M, Flokstra-de Blok BM, Oude Elberink JN. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy. 2016;71(11):1585\u201393. https:\/\/doi.org\/10.1111\/all.12920.","journal-title":"Allergy"},{"issue":"3","key":"1402_CR37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","volume":"114","author":"LA Beck","year":"2004","unstructured":"Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fc\u03b5RI expression and function. J Allergy Clin Immunol. 2004;114(3):527\u201330. https:\/\/doi.org\/10.1016\/j.jaci.2004.06.032.","journal-title":"J Allergy Clin Immunol"},{"key":"1402_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1600-065X.2007.00519.x","volume":"217","author":"TC Theoharides","year":"2007","unstructured":"Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev. 2007;217:65\u201378. https:\/\/doi.org\/10.1111\/j.1600-065X.2007.00519.x.","journal-title":"Immunol Rev"},{"issue":"1","key":"1402_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","volume":"117","author":"TB Casale","year":"2006","unstructured":"Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2005.09.036.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1402_CR40","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jaci.2007.07.041","volume":"120","author":"MF Sands","year":"2007","unstructured":"Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007;120(4):979\u201381. https:\/\/doi.org\/10.1016\/j.jaci.2007.07.041.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1402_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","volume":"68","author":"PJ Lowe","year":"2009","unstructured":"Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68(1):61\u201376. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03401.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1-2","key":"1402_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jim.2005.06.008","volume":"303","author":"RG Hamilton","year":"2005","unstructured":"Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods. 2005;303(1-2):81\u201391. https:\/\/doi.org\/10.1016\/j.jim.2005.06.008.","journal-title":"J Immunol Methods"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-022-01402-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-022-01402-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-022-01402-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T19:04:52Z","timestamp":1673636692000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-022-01402-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1402"],"URL":"https:\/\/doi.org\/10.1186\/s13052-022-01402-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2054288\/v1","asserted-by":"object"}]},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The parents of the child described in this case report gave their written consent to publish the informations prior to submission (kept in medical record).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}